Dracen raises $40M series A

Dracen Pharmaceutical Inc. (Baltimore, Md.) closed a tranched $40 million series A round led by new investor Deerfield Management on March 22. New investors Osage University Partners and i&i Prague also participated.

President and CEO Thomas Estok told BioCentury the tranches are triggered by development milestones, but declined to disclose details...